SCHEMBL303078

SCHEMBL303078

O=C1NCCN1c1cccc(N(Cc2ccc(Cl)cc2)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.55
PKM P14618 1/20 0.54
CNR1 P21554 3/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
HTR1A P08908 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR7 P34969 1/20 0.46
DRD3 P35462 1/20 0.46
HTR6 P50406 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 1/20 0.45
PGR P06401 2/20 0.44
NR3C1 P04150 1/20 0.44
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 2/20 0.42
PTPN22 Q9Y2R2 2/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965541 0.93 KMT2A (0.52) CNR2PKMCNR1KMT2AMEN1
SCHEMBL302086 0.84 CNR2 (0.43) CNR2PKMCNR1KMT2AMEN1
SCHEMBL302140 0.80 HTR2C (0.47) CNR2KMT2AMEN1HTR1AHTR2A
SCHEMBL309786 0.80 CNR2 (0.38) CNR2PKMCNR1KMT2AMEN1
SCHEMBL1971605 0.79 CNR2 (0.38) CNR2PKMCNR1KMT2AMEN1
SCHEMBL1989680 0.78 HTR2C (0.37) CNR2PKMCNR1KMT2AMEN1
SCHEMBL3276020 0.77 HTR6 (0.42) KMT2AMEN1HTR1AHTR2AHTR2C
SCHEMBL303519 0.77 HTR2C (0.45) CNR2CNR1KMT2AMEN1HTR1A
SCHEMBL1966437 0.75 HTR7 (0.69) CNR2CNR1KMT2AMEN1HTR1A
SCHEMBL2773437 0.74 CNR2 (0.60) CNR2PKMKMT2AMEN1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP claimed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US claimed
JP-2012500835-A 2012-01-12 JP claimed
EP-2334637-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-06-22 EP claimed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 CNR2 780/4885PKM 444/4885CNR1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.